VDM11 – 25 mg

Brand:
Cayman
CAS:
313998-81-1
Storage:
-20
UN-No:
De Minimis - 1170 / 3

Numerous analogs of arachidonoyl ethanolamide (AEA) potentiate its biological activity. This potentiation is ascribed either to inhibition of AEA reuptake into neurons, or inhibition of fatty amide acyl hydrolase (FAAH) within the neurons.{10254,10647} VDM11 is an AEA transport inhibitor with essentially no activity on either the central cannabinoid receptor (CB1), peripheral cannabinoid receptor (CB2), or the vanilloid receptor 1 (VR1).{9577} However, VDM11 inhibits FAAH and monoacylglycerol lipase (MAGL) and may act as an alternative FAAH substrate.{14077} At a concentration of 3 µM, VDM11, like AM404, inhibits glutamergic synaptic transmission between hippocampal neurons.{12853} The mechanism of this effect may be a direct action on sodium channels. Thus, the use of anandamide analogs as uptake inhibitors and interpretation of the results must be undertaken with care.  

 

Available on backorder

SKU: 10006731 - 25 mg Category:

Description

An AEA transport inhibitor with essentially no activity on the CB1 receptor, CB2 receptor, or TRPV1; inhibits FAAH and MAGL and may act as an alternative FAAH substrate; inhibits glutamergic synaptic transmission between hippocampal neurons at a concentration of 3 µM


Formal name: N-(4-hydroxy-2-methylphenyl)-5Z,8Z,11Z,14Z-eicosatetraenamide

Synonyms: 

Molecular weight: 409.6

CAS: 313998-81-1

Purity: >98%

Formulation: A solution in ethanol


Product Type|Biochemicals|Small Molecule Inhibitors|Fatty Acid Metabolism||Product Type|Biochemicals|Small Molecule Inhibitors|Glycerolipid Lipases||Product Type|Biochemicals|Transporter & Exchanger Modulators||Research Area|Lipid Biochemistry|Endocannabinoid/Endocannabinoid-like||Research Area|Lipid Biochemistry|Glycerolipids|Lipases||Research Area|Lipid Biochemistry|Lipid Transport||Research Area|Neuroscience|Cannabinoid Research|Endocannabinoids